NEU continues PMS P3 preparations after positive FDA meeting
Filed with ASX · · 3 pages · English
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Phase 2 trial shows significant improvements in Angelman
- Q2 2024 update
- Phase 2 trial shows significant improvements in Pitt Hopkins
- DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
- Q1 2024 quarterly activity and cash flow report
Later from Neuren Pharmaceuticals
- DAYBUE receives marketing authorization in Canada
- PRV sold for US$150m - Neuren to receive one third
- Q3 2024 update
- Neuren announces A$50m on-market share buy-back program
- Trofinetide marketing application submitted in Europe
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals